By Sam Robinson
Publication Date: 2026-10-18 08:00:00
NVIDIA’s healthcare involvement
NVIDIA’s collaboration with Danaher builds on its wider push to apply AI across healthcare and life sciences, from drug discovery and medical imaging to clinical workflows and laboratory automation.
Its BioNeMo platform provides tools and models for AI-driven biology, supporting applications including molecular design, protein structure prediction and virtual screening.
The company is also working with pharmaceutical leaders to integrate AI into research and development.
In January 2026, NVIDIA and Eli Lilly announced plans for a co-innovation lab focused on drug discovery, while Roche is deploying NVIDIA computing infrastructure to support pharmaceutical research, diagnostics and manufacturing.
This growing ecosystem reflects NVIDIA’s ambition to connect AI models with real-world scientific data and experimentation.
Danaher – key partners
Automata
CEO: Mostafa ElSayed | HQ: London, UK
Automata is a laboratory automation company developing AI-ready infrastructure for life sciences research. Its LINQ platform connects laboratory instruments, robotics and software to automate complex experimental workflows. Danaher invested in Automata’s US$45m Series C in January 2026, while Automata’s technology is being used for device orchestration and robotic automation in Danaher’s upcoming autonomous lab.
AstraZeneca
CEO: Pascal Soriot | HQ: Cambridge, UK
AstraZeneca is a global biopharmaceutical company focused on…
